Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing with new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Maruho Co., Ltd. engages in the research, development, manufacture, and marketing of pharmaceutical products. It specializes in the production of dermatology and topical drugs. Its products include Hirudoid Cream, Eksalb, Rozex Gel, Casal Cream, Farom Tablets, and Telgin G Dry Syrup. The company was founded by Eikuma Koba in July 1915 and is headquartered in Osaka, Japan.

The Texas A&M University System creates a seamless pathway for students to earn an associate and bachelor’s degree in related fields

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of Research Institutes publicly funded by the federal and the state governments of Germany. Additionally, the Max Planck Society and its Institutes receive third party funding from public and private contributions and from the European Union. The world leading organization is named in honor of its former president, theoretical physicist Max Planck. The 86 Institutes and Research Facilities of the Max Planck Society (as of 2020) conduct basic research in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 24,000 permanent employees, including 15,000 scientists, and around 5,000 non-tenured scientists and guests. As of December 31, 2018, the proportion of female employees was 44.4 percent. The Max Planck Society (with its 86 Max Planck Institutes) has a world-leading reputation as a science and technology research organization, with more than 33 Nobel Prizes awarded to its scientists, and is widely regarded as one of the foremost basic research organizations in the world.

Lemonex Co., Ltd.is engaged in developing and commercializing cancer immunotherapeutic, antibody therapeutics and gene therapeutics. The company was founded on December 17, 2013 and is headquartered in Seoul, South Korea.

Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.

Chongqing Linbao Biotechnology Co., Ltd., established on 2014-11-18, Business scope includes general items:disinfectant(Does not contain drugs)production and sales;Health Supplies,Class I medical device,Production and sales of Class II medical devices;biology,Mobile Wearables,Biotechnology,biopharmaceutical products,technical consulting,Technical Services,technology transfer;agricultural product,Research and development of Chinese herbal medicine technology,to plant,Sales;cosmetic,Daily necessities,Sales of prepackaged food;business management,market management,marketing planning.(Business items subject to approval,Can operate after obtaining approval)**(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

The Chemo-Sero Therapeutic Research Institute operates as a pharmaceutical company specializing in the field of biotechnology, immunology, hematology, and microbiology. It develops and manufactures vaccines and blood plasma products. The firm's products include human and veterinary vaccines, diagnostic antigens, and treatments for congenital disorders. They also provides newborn screening tests and quality assurance systems solutions. The company was founded on December 26, 1945 and is headquartered in Kumamoto, Japan.

Yantai Enmeinuo Biotechnology Co., Ltd., established on 2018-11-21, Business scope includes licensed projects:Health food sales;food business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Health Consulting Services(Does not include medical services);Cosmetics Wholesale;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Communication equipment sales;Instrument sales;Machinery sales;Chemical product sales(No licensed chemical products).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shenzhen China Resources Jiuchuang Pharmaceutical Co., Ltd., established on 2018-02-08, Business scope includes general business items:Research and development of chemical raw materials;Research and development of chemical preparations.(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating),The licensing program is:Manufacture and sales of chemical raw materials;Manufacture and sale of chemical preparations.

Sandoz AG, a subsidiary of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.